An interventional study of Transfer Energy Capacitive and Resistive (TECAR) [ SMART TECAR } and Standard Hand Rehabilitation [ US } in Carpal Tunnel Syndrome (CTS) Post-burn, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Carpal Tunnel Syndrome by Cairo University — 9 open to participants now, 10 under way, none of them phase 3. Carpal Tunnel Syndrome · Cairo University.
Among the 21 studies in Carpal Tunnel Syndrome by Cairo University, this one is the 12th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2026, is one of 19 with no phase, and was the 21st registered.
591 studies on the registry are indexed under Carpal Tunnel Syndrome; 133 are open to participants now.
Browse Carpal Tunnel Syndrome studies →9 of the 21 studies in Carpal Tunnel Syndrome by Cairo University are open now, in 1 country. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 40–60 · Women only
Cairo University · Sites in Egypt
Ages 25–35 · Women only
Cairo University · Sites in Egypt
Ages 20–60
Cairo University · Sites in Egypt
Ages 40–60 · Women only
Cairo University · Sites in Egypt
Ages 25–35 · Women only
By country, each count listing its studies:
Of the 72 Carpal Tunnel Syndrome studies recruiting now, 27 (38%) set no upper age limit and 36 (50%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.
This study: 20 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 52 is below the median of 60 across 446 interventional studies indexed under Carpal Tunnel Syndrome.
Median enrollment 55 across the 20 interventional studies, 119 across the 1 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Carpal Tunnel Syndrome by Cairo University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Carpal Tunnel Syndrome (CTS) is a common entrapment neuropathy that can develop as a secondary complication following deep burns involving the hand or wrist. Post-burn CTS arises due to factors such as fibrosis, edema, and scar contracture, which may increase pressure on the median nerve within the carpal tunnel, leading to significant pain, sensory disturbances, and impaired hand function Recent studies support the effectiveness of Transfer Energy Capacitive and Resistive (TECAR ) therapy in idiopathic CTS, showing improvements in pain, symptom severity, and function, as measured by validated tools such as the Boston Carpal Tunnel Questionnaire (BCTQ) and Visual Analogue Scale (VAS).
A study reported that both TECAR and ultrasound groups showed significant symptom improvement after treatment, although ultrasound had more sustained effects on median nerve cross-sectional area at 3 months
This study will involve 52 patients diagnosed with CTS post-burn; they will receive TECAR as an intervention. The outcome measures include ( VAS, Arabic version of Boston Carpal Tunnel Questionnaire, and Camry Digital Handgrip Dynamometer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive TECAR therapy at a frequency of 0.5 MHz and intensity of 30 to 50% and medium Capacitive Energy Transfer electrode (60 mm), 5 min capacitive (CAP) and 10 min resistive (RES), three sessions per week for two weeks plus standard post-burn hand rehabilitation
Device: Transfer Energy Capacitive and Resistive (TECAR) [ SMART TECAR } · Other: Standard Hand Rehabilitation [ US }
Participants in this arm will receive standard post-burn hand rehabilitation (e.g., Exercise, stretch, and US)
Other: Standard Hand Rehabilitation [ US }
TECAR therapy at a frequency of 0.5 MHz and intensity of 30 to 50% and medium Capacitive Energy Transfer electrode (60 mm), 5 min capacitive (CAP) and 10 min resistive (RES), The passive electrode was fixed to the dorsum of the hand while the active electrode was moved in a circular manner from the proximal carpal tunnel to the median nerve pathway of the palm in three sessions per week for two weeks
US using a 3 MHz probe at a dose of 1.5 watts/cm2 for 5 min intermittently for 2 weeks, 5 times a week, plus mobility and strengthening exercises
Symptom Severity
The Arabic version of the BCTQ-SSS will be used to self-report symptom severity. It consists of 11 items assessing pain, numbness, paresthesia, weakness, and nocturnal symptoms. Each item is scored from 1 (never/none) to 5 (most severe). The overall score is calculated as the mean of the items, ranging from 1 to 5, where higher scores indicate worse symptom severity.
Time frame: Baseline and 2 weeks
Functional Status
The Arabic version of the BCTQ-FSS will be used to evaluate hand function across 8 common activities. Each activity is scored from 1 (no difficulty) to 5 (cannot perform the activity at all). The total score is the mean of the items, ranging from 1 to 5, where higher scores represent greater functional impairment.
Time frame: Baseline and 2 weeks.
Grip Strength
Objective hand function and force production of the median nerve-innervated muscles will be measured using a Camry Digital Handgrip Dynamometer. Measurements are recorded in kilograms (kg), up to a maximum strength of 90 kg. Higher scores indicate greater hand grip strength.
Time frame: Baseline and 2 weeks.
Pain Intensity
Pain intensity will be measured using the Arabic version of the VAS, where patients mark their current pain level on a 10-cm line. The scale ranges from 0 cm ("no pain") to 10 cm ("worst pain"). Higher scores represent greater pain severity.
Time frame: Baseline and 2 weeks.
Plan to share: No
Started Aug 2026 (actual). Primary completion is estimated for Oct 2026, 2 months after the start.
Of 252 non-industry interventional studies with no phase under Carpal Tunnel Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's planned 2 months is below that.
Counting every sponsor, half of 262 studies reached it within 12 months; a quarter within 7 and three quarters within 26.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Oct 28, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.